Lipitor, Atorvastatin Newswire (Page 6)

Lipitor, Atorvastatin Newswire (Page 6)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 6)

Results 101 - 120 of 393 in Lipitor, Atorvastatin (generic)

  1. People's Pharmacy: Do bread and sandwiches cause you gas? - Tue, 14 Mar 2017 PSTRead the original story w/Photo

    Mar 14, 2017 | The Spokesman-Review

    When I found out that I'm gluten-intolerant, I cut bread and anything else made of flour out of my diet. All my gassiness went away.

    Comment?

  2. The 19 Best-Selling Prescription Drugs of All-TimeRead the original story w/Photo

    Mar 13, 2017 | The Motley Fool

    If you've picked up a prescription at your pharmacy anytime recently, or have been administered prescription medicines in your doctor's office or at a hospital, you probably don't need me telling you that they're exceptionally pricey . Yet, on the other side of the coin, brand-name prescription drugs are what keep the lights on for drugmakers.

    Comment?

  3. Will "Biosimilar" Medications Reduce the Cost of Biologic Drugs?Read the original story w/Photo

    Mar 9, 2017 | Scientific American

    We use cookies to provide you with a better onsite experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy .

    Comment?

  4. Atorvastatin Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2022Read the original story

    Mar 9, 2017 | Emailwire.com

    Atorvastatin is a pharmaceutical raw material in the production of atorvastatin drug , which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL cholesterol as well.

    Comment?

  5. Abstract P157: Sex Disparities in High Intensity Statin Use Following ...Read the original story

    Mar 7, 2017 | Circulation

    Background: High intensity statins have been shown to lower the risk of major cardiovascular events after an index myocardial infarction . Studies have shown that women are less likely than men to receive cardiovascular risk reduction therapies but little is known about sex differences in high intensity statin use following hospital discharge for MI.

    Comment?

  6. Stiffer penalty mulled for fake drug makersRead the original story w/Photo

    Mar 8, 2017 | The China Post

    Lawmakers of the opposition Kuomintang and the People First Party said separately Wednesday that they were considering introducing tougher laws against manufacturers of fake drugs. The announcements came a day after the Food and Drug Administration ordered a recall of all batches of the lipid-lowering drug Crestor from hospitals, clinics and pharmacies, after a second batch of the medication was found to have been mixed with counterfeit drugs.

    Comment?

  7. More knockoff drugs uncoveredRead the original story w/Photo

    Mar 7, 2017 | The China Post

    The Food and Drug Administration ordered a recall Tuesday of Taiwan's most widely used lipid-lowering drug after more counterfeit versions of the drug were found. The drug's maker, pharmaceutical giant AstraZeneca, issued a statement through its Taiwan affiliate on Tuesday announcing a recall of the Crestor drug in a joint effort with the FDA.

    Comment?

  8. Esperion Announces Initiation Of Phase 2 Triplet Oral Therapy Study...Read the original story

    Mar 6, 2017 | BioSpace

    Esperion Therapeutics, Inc. , the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today announced the initiation of a Phase 2 clinical study to assess the efficacy and safety of triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin in patients with hypercholesterolemia. This non-registrational study will enable the Company to explore the potential market dynamics of these complementary oral LDL-C lowering therapies together.

    Comment?

  9. People's Pharmacy: Investigate source of prescription drugs for clues on qualityRead the original story w/Photo

    Mar 6, 2017 | Athens Banner-Herald

    How does a person know if a drug he or she is taking is produced in a foreign country, diluted or even filled with harmful chemicals? Your questions are challenging. Although food and clothing are labeled with country of origin, medications are not.

    Comment?

  10. atorvastatinRead the original story w/Photo

    Mar 2, 2017 | MedicineNet

    John P. Cunha, DO, is a U.S. board-certified Emergency Medicine Physician. Dr. Cunha's educational background includes a BS in Biology from Rutgers, the State University of New Jersey, and a DO from the Kansas City University of Medicine and Biosciences in Kansas City, MO.

    Comment?

  11. Pfizer Stock History: How the Drugmaker Became an Industry GiantRead the original story

    Feb 28, 2017 | The Motley Fool

    Yet it took nearly a century after its 1849 founding before Pfizer started to press forward with large-scale production of penicillin, which helped redefine the company's future path as a pharmaceutical giant. Now, Pfizer is the company behind a wide variety of treatments to make people healthier, but its stock has gone on a roller-coaster ride that has left even some long-term investors with returns that leave something to be desired.

    Comment?

  12. How Well Do You Know the Grapefruit Drug Interaction?Read the original story

    Feb 23, 2017 | Pharmacy Times

    Prescribers, pharmacists, direct-to-consumer advertising, and patient leaflets mention grapefruit-induced drug interactions with a variety of common medications. For example, grapefruit can increase atorvastatin and decrease fexofenadine levels in the body.1 But is grapefruit special? The most significant offending natural compound, bergamottin , prevents the breakdown of medications through the most numerous and often used metabolizing enzyme .

    Comment?

  13. at the press club, kambraRead the original story w/Photo

    Feb 21, 2017 | Your Democracy

    He is a member of the Republican Party. In 2012, He launched the Energy and Enterprise Initiative, a "nationwide public engagement campaign promoting conservative and free-enterprise solutions to energy and climate challenges".

    Comment?

  14. Esperion Provides Bempedoic Acid Development Program Update; Reports...Read the original story

    Feb 21, 2017 | BioSpace

    Esperion Therapeutics, Inc. , the lipid management company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol , today provided bempedoic acid development program updates and financial results for the fourth quarter and full year ended December 31, 2016. "Last year, Esperion was focused on building a strong foundation for the development and initiation of our global pivotal Phase 3 clinical development program for bempedoic acid, which the team successfully initiated, including the CLEAR Outcomes cardiovascular outcomes trial," said Tim M. Mayleben, president and chief executive officer of Esperion.

    Comment?

  15. Big dangers of mixing medicationRead the original story w/Photo

    Feb 19, 2017 | KRISTV.COM Corpus Christi

    Anytime you take more than one medication, or even mix it with certain foods, beverages, or over-the-counter medicines, you are at risk of a drug interaction. Most drug interactions are not serious, but because a few are, it is important to understand the possible outcome before you take your medications.

    Comment?

  16. MKSAP: 74-year-old woman with altered mental statusRead the original story w/Photo

    Feb 18, 2017 | Kevin, M.D.

    A 74-year-old woman is evaluated in the emergency department for several hours of altered mental status. She is from out-of-state and is visiting with relatives.

    Comment?

  17. Cryptic Loss of Consciousness in a 36-Year-Old WomanRead the original story

    Jul 1, 2015 | Circulation

    From the Department of Neurology and Cardiology, Heart and Brain Centre , Helsinki University Hospital and University of Helsinki, Finland; and Department of Neurology and Stroke Unit, University Hospitals of Cleveland/Case Medical Center, OH . From the Department of Neurology and Cardiology, Heart and Brain Centre , Helsinki University Hospital and University of Helsinki, Finland; and Department of Neurology and Stroke Unit, University Hospitals of Cleveland/Case Medical Center, OH .

    Comment?

  18. How to Image Cardiac AmyloidosisRead the original story

    May 1, 2014 | Circulation

    From the Noninvasive Cardiovascular Imaging Program, Division of Cardiology, Departments of Radiology and Medicine , Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , and Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine , Brigham and Women's Hospital, Harvard Medical School, Boston, MA. From the Noninvasive Cardiovascular Imaging Program, Division of Cardiology, Departments of Radiology and Medicine , Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , and Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine , Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

    Comment?

  19. Implications of Recent Clinical Trials for the National Cholesterol...Read the original story

    Jul 13, 2004 | Circulation

    The Adult Treatment Panel III of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published.

    Comment?

  20. In Focus BlogPraluent to Stay on Market as PCSK9 Patent War Continues in CourtRead the original story w/Photo

    Feb 10, 2017 | The American Journal of Managed Care

    Attorneys for Sanofi, a sponsor of Praluent, said the public interest in having more than one drug available in the PCSK9 class would be an important part of their claim. Praluent, the first drug approved in the cholesterol-fighting drug class called PCSK9 inhibitors, won't be pulled from the shelves while sponsors Sanofi and Regeneron battle in federal court over Amgen's patent claim for rival Repatha.

    Comment?